NCT07647068

Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-08-15Est. Completion: 2027-12-31

Enrollment target: 59 participants

Locations

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Contact

The Ohio State University Comprehensive Cancer CenterOSUCCCClinicaltrials@osumc.edu 1-800-293-5066

Other microbiome trials you might be interested in

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)Phase 2Recruiting

Locally Advanced Gastrointestinal Stromal TumorLocally Advanced SarcomaMetastatic Gastrointestinal Stromal TumorMetastatic SarcomaStage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8

This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of prot…

Duarte, United StatesEst. completion Jul 1, 2026

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.